Skip to main content
. Author manuscript; available in PMC: 2023 Dec 3.
Published in final edited form as: Blood Rev. 2022 Aug 2;57:100996. doi: 10.1016/j.blre.2022.100996

Fig. 3.

Fig. 3.

Signaling pathways in acute myeloid leukemia.

Stem cell factor (SCF) binds to the KIT tyrosine kinase receptor, triggering activation of downstream RAS and PI3K. Similarly, the FLT3 ligand (FLT3-L) binds to the FLT3 tyrosine kinase receptor and activates RAS and PI3K. RAS cascades into MEK and ERK, resulting in cell proliferation. PI3K activates AKT, which leads to mTOR-driven cell growth. AKT also inhibits FOXO and other pro-apoptotic proteins, leading to cell survival.